GC Genome Corporation (KOSDAQ:340450)

Market Cap	202.92B +10.9%
Revenue (ttm)	32.64B +13.7%
Net Income	5.42B +41,017.6%
EPS	229.79 +33,695.5%
Shares Out	23.65M
PE Ratio	37.34
Forward PE	36.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	720,784
Open	8,510.00
Previous Close	8,440.00
Day's Range	8,510.00 - 9,160.00
52-Week Range	4,100.00 - 10,480.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About GC Genome

GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing. The compan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 340450

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 29, 2026

Data Sources Report a data error